Pfizer quits Duchenne gene therapy, lays off staff following study setback
Bio Pharma Dive
JULY 30, 2024
The company is letting go of 150 staffers alongside a decision to officially terminate the high-profile program, which was acquired in 2016.
Tue.Jul 30, 2024
339 
Study finds semaglutide decreases tobacco-related healthcare
Pharmaceutical Technology
JULY 30, 2024
Semaglutide, marketed as Ozempic and Wegovy, decreased tobacco-related healthcare encounters compared to other medications.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Ancient Genes of Zombie Viruses Revealed as Hidden Drivers of Cancer
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 30, 2024
When viruses pay us a visit, they sometimes leave parts of themselves behind. Silently tucked away in our genomes, some of these bits of foreign DNA can get passed down through the generations.
GSK and Flagship Pioneering link for new medicines and vaccines
Pharmaceutical Technology
JULY 30, 2024
GSK has announced a strategic collaboration with Flagship Pioneering for the discovery and development of medicines and vaccines.
How to Turn “Check-the-Box” Compliance Trainings Into Real Learning
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance trainings aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, relevant, and maybe even enjoyable! Join expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training programs. You’ll discover creative strategies to turn traditionally dry topics into meaningful learning experiences that resonate and drive real change.
Pfizer’s Bourla confident in company’s obesity drug position, despite delays
Bio Pharma Dive
JULY 30, 2024
The CEO noted how Pfizer's danuglipron could still be the second oral GLP-1 treatment to enter registrational tests after Lilly's orforglipron.
Collegium buys Ironshore for $525m and enter ADHD market
Pharmaceutical Technology
JULY 30, 2024
Collegium will pay $525m upfront to add Ironshore’s FDA-approved ADHD medication Jornay PM to its portfolio.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Ventyx scraps TYK2 inhibitor after Phase II Crohn’s defeat
Pharmaceutical Technology
JULY 30, 2024
Ventyx no longer plans to conduct additional clinical trials of VTX958 with internal resources after the Phase II trial missed its primary endpoint.
HDR UK and DPUK granted £2m for new motor neurone disease research initiative
Pharma Times
JULY 30, 2024
The rapidly progressive neurological condition affects around 5,000 people in the UK
Biotech IPO raising in Q1 2024 surged from Q4 2023 – but has the momentum lasted?
Pharmaceutical Technology
JULY 30, 2024
Biotech IPOs surged in Q1 2024, with eight completed IPOs raising a total of $3.72bn, six times more than the $621m raised in Q4 2023.
July 30, 2024: Save the Date: Meet HCRSN in St. Louis for the 2025 Annual Conference
Rethinking Clinical Trials
JULY 30, 2024
The Health Care Systems Research Network (HCSRN) will hold its 2025 Annual Conference from April 8 to 10, 2025, in St. Louis, Missouri. HCSRN is a 20-member research network focused on supporting research institutes aligned with healthcare delivery systems. HCSRN’s mission is to improve individual and population health through research that connects the resources and capabilities of learning healthcare systems.
Clinical Research White Paper – Enhancing Transparency & Efficiency Throughout the Trial Lifecycle
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Roche’s Vabysmo challenges Eylea dominance with third European indication
Pharmaceutical Technology
JULY 30, 2024
The European Commission (EC) has approved Vabysmo (faricimab) for the treatment of retinal vein occlusion.
Incyte trims cancer drug pipeline in R&D refocus
Bio Pharma Dive
JULY 30, 2024
The company will stop developing five experimental treatments, including two oral checkpoint inhibitors targeting PD-L1.
Boehringer Ingelheim acquires Nerio Therapeutics for $1.3bn
Pharmaceutical Technology
JULY 30, 2024
Boehringer Ingelheim has acquired Nerio Therapeutics, a drug discovery and development company, in a deal valued at $1.3bn.
Talk of the Towne episode 11: American Kidney Fund
Antidote
JULY 30, 2024
In the latest installment of Talk of the Towne, we sat down with Melanie Paris, M.A., MPH, the Senior Director of Strategic Partnerships and Kidney Disease Education at the American Kidney Fund (AKF). In the discussion, we got her insights into the types of kidney disease, treatment disparities, and the importance of clinical research in the field. She also shared many valuable resources for individuals and their loved ones living with kidney disease, which are linked here.
Can Your Organization Spot a Conflict Before It’s a Crisis?
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
NICE not to recommend Daiichi Sankyo-AstraZeneca’s Enhertu for NHS
Pharmaceutical Technology
JULY 30, 2024
The UK NICE has decided not to recommend Daiichi Sankyo and AstraZeneca’s Enhertu for advanced HER2-low breast cancer for NHS use.
A symbiotic relationship for optimal AI-powered healthcare
pharmaphorum
JULY 30, 2024
Discover how OPEN Health and fusion's AI technology partnership is creating a symbiotic relationship that is revolutionising healthcare. Explore the benefits of this for optimal patient care.
FDA grants priority review for Novartis’ leukaemia treatment
Pharmaceutical Technology
JULY 30, 2024
The US FDA has granted priority review designation for Novartis’ Scemblix for Ph-positive chronic myeloid leukemia in the chronic phase.
Boehringer buys oncology player Nerio in $1.3bn deal
pharmaphorum
JULY 30, 2024
Boehringer buys Nerio Therapeutics for $1.
White Paper - A Roadmap to AI Data Readiness in R&D Labs
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
Cybersecurity in clinical trials: safeguarding patient data against digital breaches
Pharmaceutical Technology
JULY 30, 2024
Trials and their partners need to adopt a strong cybersecurity strategy to protect sensitive patient data from hackers.
5 cybersecurity guidelines for remote monitoring in clinical trials
pharmaphorum
JULY 30, 2024
Implementing strong cybersecurity guidelines for remote monitoring in clinical trials is crucial to protect sensitive data. Learn these top 5 guidelines to secure your remote monitoring plan effectively.
Pfizer tacks on $1B to 2024 revenue outlook amid cost-cutting drive
Fierce Pharma
JULY 30, 2024
For more than a year after Pfizer’s COVID product sales peaked at the end of 2022, the company’s quarterly revenues showed year-over-year declines. | For the first time since its sales peaked during the pandemic, Pfizer registered year-over-year revenue growth during the second quarter of 2024. And while the busy has been busy trimming operating expenses, it did add $1 billion to its total revenue projection for the year.
Older GLP-1 drug shows glimmer of benefit in Alzheimer's
pharmaphorum
JULY 30, 2024
A small study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide shows a benefit in patients with Alzheimer's disease
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharma Pulse 7/30/24: The Doctor Will See You Now, But AI May Be Listening In.The Importance of Genomic Sequencing in the Battle Against HIV in South Africa & more
Pharmaceutical Commerce
JULY 30, 2024
The latest news for pharma industry insiders.
Approaching the regulatory world with passion: CERs and EU MDR processes
pharmaphorum
JULY 30, 2024
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ethan Drower, co-founder and CEO of Cite Medical Solutions, a company providing full Clinical Evaluation Report (CER) services and industry literature review for European Union Medical Device Regulation (or EU MDR) processes.
Women in Science - Tehmina Masud - the importance of growing outside your comfort zone
BioPharma Reporter
JULY 30, 2024
A book, a computer and some sage words from her physicist father set Tehmina on her path to a successful career in science.
BioNTech cancer vaccine hits the spot in melanoma
pharmaphorum
JULY 30, 2024
mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma.The study is looking at the combination of BNT111 with Regeneron's PD-1 inhibitor Libtayo (cemiplimab) in 184 patients with advanced melanoma who have relapsed after or not responded to treatment with a PD-1/PD-L1 inhibitor, or the two therapies given alone.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Benefits of Drug Patent Licensing Agreements
Drug Patent Watch
JULY 30, 2024
The Power of Patent Licensing: Unlocking Innovation and Access to Medicines Patent licensing agreements have become a crucial tool in the pharmaceutical industry, allowing companies to collaborate and…
Circular RNA Will Soon Replace mRNA in Biopharma
BioSpace
JULY 30, 2024
The advantages of using circular RNAs—including increased durability, enhanced protein expression, and substantially lower manufacturing costs compared to linear mRNAs—have driven a spate of investment in this technology.
Salmonella Control: Comparing US and EU Regulations for Poultry
XTalks
JULY 30, 2024
Salmonella control in poultry in the US has come under intense regulatory scrutiny over the past few years. With increasing concerns about food safety, it might be worth considering whether the US should adopt the European Union’s (EU) regulatory mindset. The US Department of Agriculture’s (USDA) Food Safety and Inspection Service (FSIS) declared Salmonella an adulterant in raw breaded stuffed chicken products when contamination levels exceed one colony-forming unit (CFU) per gram.
Explore how Lonza's experts tackle parenteral drug and bioconjugate development challenges
BioPharma Reporter
JULY 30, 2024
In the rapidly evolving field of pharmaceuticals, the development of parenteral drugs and bioconjugates presents unique challenges and opportunities.
Let's personalize your content